Jianbo Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jianbo Li has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Feng He
Department of Nephrology, Guangzhou First People's Hospital, The Second Affiliated Hospital, School of Medicine South China University of Technology Guangzhou China
6 shared publications - Wei Chen
Department of Nephrology, NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, China
6 shared publications Wei Chen
Department of Nephrology The First Affiliated Hospital, Sun Yat‐sen University Guangzhou China
5 shared publicationsZefang Dai
Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
5 shared publicationsZhong Zhong
Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
5 shared publicationsJianwen Yu
Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
4 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7554
Association of 24 h Pulse Pressure Derived from Ambulatory Blood Pressure Monitoring with All-Cause and Cardiovascular Mortality in Patients Undergoing Peritoneal Dialysis: A Prospective Cohort Study
Background/Objectives: Pulse pressure (PP), an indirect hemodynamic marker reflecting the pulsatile component of blood pressure, has been linked to adverse outcomes in dialysis patients. Whether 24 h PP (24 h PP) derived from ambulatory BP monitoring (ABPM) is independently associated with all-cause and cardiovascular (CV) mortality in peritoneal dialysis (PD) patients remains unclear. Methods: This sub-cohort, nested within a single-center prospective PD database, enrolled 165 patients with baseline 24 h ABPM. The 24 h PP was analyzed continuously and in tertiles. All-cause mortality was assessed by Cox regression and CV mortality by Fine–Gray competing-risk modeling. The median follow-up was 47.4 months, counted from the date of ABPM completion. Results: During follow-up, 48 patients (29.1%) died, including 28 CV deaths (58.3% of all deaths). Per 1-SD increment in 24 h PP, the adjusted hazard ratio (HR) for all-cause mortality was 1.39 (95% confidence interval [CI] 1.03–1.87; p = 0.032), and the adjusted subdistribution hazard ratio (SHR) for CV mortality was 1.44 (95% CI 1.06–1.94; p = 0.018). The highest tertile showed elevated risks of all-cause (HR 3.47; 95% CI 1.12–10.70; p = 0.031) and CV mortality (SHR 5.11; 95% CI 1.32–19.79; p = 0.018) versus the lowest, persisting after adjustment for office PP. Conclusions: Elevated ABPM-derived 24 h PP is independently associated with increased all-cause and CV mortality in PD patients after adjustment for office PP.
- 29 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7554
Open AccessAssociation of 24 h Pulse Pressure Derived from Ambulatory Blood Pressure Monitoring with All-Cause and Cardiovascular Mortality in Patients Undergoing Peritoneal Dialysis: A Prospective Cohort Study
Background/Objectives: Pulse pressure (PP), an indirect hemodynamic marker reflecting the pulsatile component of blood pressure, has been linked to adverse outcomes in dialysis patients. Whether 24 h PP (24 h PP) derived from ambulatory BP monitoring (ABPM) is independently associated with all-cause and cardiovascular (CV) mortality in peritoneal dialysis (PD) patients remains unclear. Methods: This sub-cohort, nested within a single-center prospective PD database, enrolled 165 patients with baseline 24 h ABPM. The 24 h PP was analyzed continuously and in tertiles. All-cause mortality was assessed by Cox regression and CV mortality by Fine–Gray competing-risk modeling. The median follow-up was 47.4 months, counted from the date of ABPM completion. Results: During follow-up, 48 patients (29.1%) died, including 28 CV deaths (58.3% of all deaths). Per 1-SD increment in 24 h PP, the adjusted hazard ratio (HR) for all-cause mortality was 1.39 (95% confidence interval [CI] 1.03–1.87; p = 0.032), and the adjusted subdistribution hazard ratio (SHR) for CV mortality was 1.44 (95% CI 1.06–1.94; p = 0.018). The highest tertile showed elevated risks of all-cause (HR 3.47; 95% CI 1.12–10.70; p = 0.031) and CV mortality (SHR 5.11; 95% CI 1.32–19.79; p = 0.018) versus the lowest, persisting after adjustment for office PP. Conclusions: Elevated ABPM-derived 24 h PP is independently associated with increased all-cause and CV mortality in PD patients after adjustment for office PP.
- Open Access
- 19 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7300
Nighttime Systolic Blood Pressure and Cardiovascular and All-Cause Mortality in Peritoneal Dialysis Patients: A Single-Center Prospective Cohort Study
Background/Objectives: The link between ambulatory-blood-pressure-derived measurements and survival outcomes among patients receiving peritoneal dialysis (PD) remains uncertain. This study sought to explore whether nighttime systolic blood pressure (SBP) obtained from 24-h ambulatory blood pressure monitoring (ABPM) is associated with cardiovascular (CV) and all-cause mortality in PD individuals. Methods: Between 1 January 2017 and 30 June 2021, this single-center sub-cohort study (derived from a prospective database of PD) enrolled 165 PD participants with a median follow-up of 47.4 months from the date of ABPM completion. Competing risk regression was applied to estimate the association between nighttime SBP and CV mortality, accounting for competing death events. Multivariable Cox proportional hazards regression was utilized to quantify nighttime SBP’s independent correlation with all-cause mortality. Results: Over the follow-up period, 48 patients (29.1%) died, with 28 (58.3%) cases attributed to CV causes. In the fully adjusted model, each 1 SD rise in nighttime SBP corresponded to a subdistribution hazard ratio (SHR) of 1.53 (95% confidence interval [CI], 1.05–2.21; p = 0.026) for CV mortality. In the Cox regression model, every 1 SD increase in nighttime SBP showed an independent association with a 42% excess risk of all-cause mortality (hazard ratio [HR] = 1.42, 95% CI, 1.04–1.93; p = 0.026). Quartile-stratified analyses indicated that participants within the uppermost nighttime SBP quartile exhibited higher mortality risk for both endpoints compared to those in the lowest quartile. Conclusions: Elevated nighttime SBP is associated with increased CV and all-cause mortality risk in PD patients.
- 19 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7300
Open AccessNighttime Systolic Blood Pressure and Cardiovascular and All-Cause Mortality in Peritoneal Dialysis Patients: A Single-Center Prospective Cohort Study
Background/Objectives: The link between ambulatory-blood-pressure-derived measurements and survival outcomes among patients receiving peritoneal dialysis (PD) remains uncertain. This study sought to explore whether nighttime systolic blood pressure (SBP) obtained from 24-h ambulatory blood pressure monitoring (ABPM) is associated with cardiovascular (CV) and all-cause mortality in PD individuals. Methods: Between 1 January 2017 and 30 June 2021, this single-center sub-cohort study (derived from a prospective database of PD) enrolled 165 PD participants with a median follow-up of 47.4 months from the date of ABPM completion. Competing risk regression was applied to estimate the association between nighttime SBP and CV mortality, accounting for competing death events. Multivariable Cox proportional hazards regression was utilized to quantify nighttime SBP’s independent correlation with all-cause mortality. Results: Over the follow-up period, 48 patients (29.1%) died, with 28 (58.3%) cases attributed to CV causes. In the fully adjusted model, each 1 SD rise in nighttime SBP corresponded to a subdistribution hazard ratio (SHR) of 1.53 (95% confidence interval [CI], 1.05–2.21; p = 0.026) for CV mortality. In the Cox regression model, every 1 SD increase in nighttime SBP showed an independent association with a 42% excess risk of all-cause mortality (hazard ratio [HR] = 1.42, 95% CI, 1.04–1.93; p = 0.026). Quartile-stratified analyses indicated that participants within the uppermost nighttime SBP quartile exhibited higher mortality risk for both endpoints compared to those in the lowest quartile. Conclusions: Elevated nighttime SBP is associated with increased CV and all-cause mortality risk in PD patients.
- Open Access
- 21 April 2026
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 20 (1)
Pulmonary nodules in a case of microscopic polyangiitis: a case report and review of the literature
Microscopic polyangiitis (MPA) is a type of small-vessel vasculitis that can lead to organ damage, primarily affecting the kidneys and lungs. We described
- 21 April 2026
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 20 (1)
Open AccessPulmonary nodules in a case of microscopic polyangiitis: a case report and review of the literature
Microscopic polyangiitis (MPA) is a type of small-vessel vasculitis that can lead to organ damage, primarily affecting the kidneys and lungs. We described
- Open Access
- 13 April 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (4) , e70424
Characterization of NLRP3 Inflammasome‐Associated Hub Genes in the Progression of Diabetic Nephropathy
Background: Diabetic nephropathy (DN) is widely recognized as the primary cause of end‐stage renal disease. However, the underlying mechanisms and pathogenesis of DN remain incompletely understood. Exploring novel biomarkers aiding in tracking the progression of DN has important clinical implications. Methods: Human renal transcriptomic datasets (GSE142025 and GSE96804) from the Gene Expression Omnibus (GEO) were analyzed. Differentially expressed genes (DEGs) were identified using a staged analysis, which involved sequential comparisons between normal controls and early‐stage DN, as well as between early DN (eDN) and advanced DN (aDN). Enrichment analysis of DEGs was performed using R software. WGCNA was utilized to construct gene co‐expression networks and to identify the key genes. Then, Venn diagrams were generated using DEGs and key genes from both datasets to determine the final hub genes. ROC curves were then used to assess the diagnostic accuracy of hub genes for DN disease progression. Finally, we cross‐validated the hub genes using the clinical kidney specimens. Results: After analyzing the datasets, we identified 22 and 43 hub genes using the WGCNA and DEGs at the eDN and aDN stages. Further investigation of the literature on the hub genes led to the discovery of their association with the activity of NLRP3 inflammasome, including ZFP36 , CLEC2D , and HCK , which were identified as NLRP3 inflammasome‐associated hub genes (NIAHGs). We found that the AUC of all the NIAHGs can indicate their potential diagnostic value. Then, we validated the expression levels of NIAHGs in human renal tissues, which were consistent with those in both data sets. Importantly, immunoblot analysis indicated that NIAHGs expression was associated with NLRP3 inflammasome activation. Furthermore, NLRP3 inflammasome was significantly activated, leading to the release of large amounts of IL‐1β and IL‐18 in eDN, further initiating the inflammatory response in the diabetic kidney. Conclusions: Our findings identify critical hub genes associated with DN progression and NLRP3 inflammasome activity, providing a theoretical basis and candidate targets for subsequent research.
- 13 April 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (4) , e70424
Open AccessCharacterization of NLRP3 Inflammasome‐Associated Hub Genes in the Progression of Diabetic Nephropathy
Background: Diabetic nephropathy (DN) is widely recognized as the primary cause of end‐stage renal disease. However, the underlying mechanisms and pathogenesis of DN remain incompletely understood. Exploring novel biomarkers aiding in tracking the progression of DN has important clinical implications. Methods: Human renal transcriptomic datasets (GSE142025 and GSE96804) from the Gene Expression Omnibus (GEO) were analyzed. Differentially expressed genes (DEGs) were identified using a staged analysis, which involved sequential comparisons between normal controls and early‐stage DN, as well as between early DN (eDN) and advanced DN (aDN). Enrichment analysis of DEGs was performed using R software. WGCNA was utilized to construct gene co‐expression networks and to identify the key genes. Then, Venn diagrams were generated using DEGs and key genes from both datasets to determine the final hub genes. ROC curves were then used to assess the diagnostic accuracy of hub genes for DN disease progression. Finally, we cross‐validated the hub genes using the clinical kidney specimens. Results: After analyzing the datasets, we identified 22 and 43 hub genes using the WGCNA and DEGs at the eDN and aDN stages. Further investigation of the literature on the hub genes led to the discovery of their association with the activity of NLRP3 inflammasome, including ZFP36 , CLEC2D , and HCK , which were identified as NLRP3 inflammasome‐associated hub genes (NIAHGs). We found that the AUC of all the NIAHGs can indicate their potential diagnostic value. Then, we validated the expression levels of NIAHGs in human renal tissues, which were consistent with those in both data sets. Importantly, immunoblot analysis indicated that NIAHGs expression was associated with NLRP3 inflammasome activation. Furthermore, NLRP3 inflammasome was significantly activated, leading to the release of large amounts of IL‐1β and IL‐18 in eDN, further initiating the inflammatory response in the diabetic kidney. Conclusions: Our findings identify critical hub genes associated with DN progression and NLRP3 inflammasome activity, providing a theoretical basis and candidate targets for subsequent research.
- Open Access
- 1 January 2026
- Published by S. Karger AG in Kidney Diseases
- Vol. 12 (1) , 527-538
Interstitial Fibrosis and Tubular Atrophy as a Predictor of Renal Outcomes in Patients with Malignant Hypertension-Related Thrombotic Microangiopathy: A Multicentric Cohort Study
Introduction: Interstitial fibrosis and tubular atrophy (IFTA) are common pathological findings in patients with malignant hypertension (mHTN)-related thrombotic microangiopathy (TMA), but their predictive value for renal outcomes in this population remains unclear. Methods: This study included patients with mHTN-related TMA confirmed by renal biopsy, admitted to seven different Chinese hospitals from January 2008 to October 2024. Patients were stratified into mild/moderate, severe, and extremely severe IFTA groups based on renal biopsy findings. The primary outcome was renal replacement therapy (RRT) dependence during follow-up, while the secondary outcome was renal function recovery. Results: A total of 465 patients (median age: 35 years, 87.74% male) were included in this study. During a median follow-up of 24 months, RRT dependence occurred in 182 patients and renal function recovery occurred in 226 patients. Kaplan-Meier analysis showed higher RRT risk with more severe IFTA. Cox regression models showed that severe and extremely severe IFTA groups had hazard ratios of 2.29 (95% CI: 1.59–3.28) and 8.00 (95% CI: 5.36–11.95) for RRT dependence compared to mild/moderate IFTA group (both p < 0.05), even after adjusting for clinical variables and the proportion of global glomerulosclerosis. The cumulative probability of renal function recovery also differed among IFTA groups (log-rank p < 0.001). Extremely severe IFTA negatively impacted renal function recovery in unadjusted analysis, but this significance disappeared after adjusting for the proportion of global glomerulosclerosis. Conclusion: IFTA may serve as a valuable and independent predictor of renal outcomes in patients with mHTN-related TMA, highlighting its importance for clinical decision-making.
- 1 January 2026
- Published by S. Karger AG in Kidney Diseases
- Vol. 12 (1) , 527-538
Open AccessInterstitial Fibrosis and Tubular Atrophy as a Predictor of Renal Outcomes in Patients with Malignant Hypertension-Related Thrombotic Microangiopathy: A Multicentric Cohort Study
Introduction: Interstitial fibrosis and tubular atrophy (IFTA) are common pathological findings in patients with malignant hypertension (mHTN)-related thrombotic microangiopathy (TMA), but their predictive value for renal outcomes in this population remains unclear. Methods: This study included patients with mHTN-related TMA confirmed by renal biopsy, admitted to seven different Chinese hospitals from January 2008 to October 2024. Patients were stratified into mild/moderate, severe, and extremely severe IFTA groups based on renal biopsy findings. The primary outcome was renal replacement therapy (RRT) dependence during follow-up, while the secondary outcome was renal function recovery. Results: A total of 465 patients (median age: 35 years, 87.74% male) were included in this study. During a median follow-up of 24 months, RRT dependence occurred in 182 patients and renal function recovery occurred in 226 patients. Kaplan-Meier analysis showed higher RRT risk with more severe IFTA. Cox regression models showed that severe and extremely severe IFTA groups had hazard ratios of 2.29 (95% CI: 1.59–3.28) and 8.00 (95% CI: 5.36–11.95) for RRT dependence compared to mild/moderate IFTA group (both p < 0.05), even after adjusting for clinical variables and the proportion of global glomerulosclerosis. The cumulative probability of renal function recovery also differed among IFTA groups (log-rank p < 0.001). Extremely severe IFTA negatively impacted renal function recovery in unadjusted analysis, but this significance disappeared after adjusting for the proportion of global glomerulosclerosis. Conclusion: IFTA may serve as a valuable and independent predictor of renal outcomes in patients with mHTN-related TMA, highlighting its importance for clinical decision-making.
- 14 December 2025
- Published by Wiley in Nephrology
- Vol. 30 (12) , e70157
Dual Anti‐Neutrophil Cytoplasmic Antibody and Anti‐Glomerular Basement Membrane Antibody‐Positive Crescentic Glomerulonephritis in a Patient With Monoclonal Gammopathy and Elevated IgG4 Levels: A Case Report and Literature Review
The aetiology of crescentic glomerulonephritis is multifactorial, with anti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis (AAV) and anti‐glomerular basement membrane (GBM) antibody disease being well‐documented causes. Monoclonal immunoglobulin and immunoglobulin G4 (IgG4)‐related diseases can also exacerbate kidney damage through varying mechanisms. However, cases where both ANCA and anti‐GBM antibodies are positive, in the presence of serum M protein and elevated IgG4 levels, have not yet been reported. We herein report the first patient with dual ANCA and anti‐GBM antibody‐positive crescentic glomerulonephritis, along with monoclonal gammopathy and elevated IgG4 levels.
- 14 December 2025
- Published by Wiley in Nephrology
- Vol. 30 (12) , e70157
Dual Anti‐Neutrophil Cytoplasmic Antibody and Anti‐Glomerular Basement Membrane Antibody‐Positive Crescentic Glomerulonephritis in a Patient With Monoclonal Gammopathy and Elevated IgG4 Levels: A Case Report and Literature Review
The aetiology of crescentic glomerulonephritis is multifactorial, with anti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis (AAV) and anti‐glomerular basement membrane (GBM) antibody disease being well‐documented causes. Monoclonal immunoglobulin and immunoglobulin G4 (IgG4)‐related diseases can also exacerbate kidney damage through varying mechanisms. However, cases where both ANCA and anti‐GBM antibodies are positive, in the presence of serum M protein and elevated IgG4 levels, have not yet been reported. We herein report the first patient with dual ANCA and anti‐GBM antibody‐positive crescentic glomerulonephritis, along with monoclonal gammopathy and elevated IgG4 levels.
- Open Access
- 19 September 2025
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 39 (20) , e70105
Clinicopathological Characteristics and Prognosis of IgA Nephropathy Combined With Malignant Hypertension Kidney Injury
Background: IgA nephropathy (IgAN), a major cause of primary glomerulonephritis, is closely associated with malignant hypertension (MHT). This study aimed to explore the clinicopathological characteristics and renal prognosis of patients with IgAN combined with malignant hypertension kidney injury (IgAN‐MHT) and investigate the associations of clinicopathological indicators with prognosis. Methods: In this single‐center retrospective cohort study, patients diagnosed with IgAN‐MHT through kidney biopsy between January 1, 2008, and June 30, 2023, in our hospital were enrolled. Cox regression models were used to assess the associations between clinical indicators and renal prognosis in IgAN‐MHT patients. Results: A total of 70 patients were included in the analysis of renal function improvement. During a median follow‐up time of 9.4 months, 26 patients (37.1%) achieved renal function improvement. Patients in the improved renal function group had higher hemoglobin levels ( p = 0.003), lower serum creatinine levels ( p = 0.006), a higher proportion of patients using sulodexide ( p = 0.018), and a lower proportion of glomerulosclerosis ( p < 0.001). Multivariable Cox regression analysis indicated that a higher proportion of glomerulosclerosis was independently associated with a lower likelihood of renal function improvement (HR = 0.97, 95% CI = 0.96–0.99, p = 0.003), while sulodexide administration was independently associated with a higher likelihood of improvement (HR = 2.75, 95% CI = 1.18–6.41, p = 0.019). Conclusion: This study revealed that in IgAN‐MHT patients, a higher proportion of glomerulosclerosis was independently associated with poorer renal outcomes, while the use of sulodexide showed a significant independent association with improved renal function.
- 19 September 2025
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 39 (20) , e70105
Open AccessClinicopathological Characteristics and Prognosis of IgA Nephropathy Combined With Malignant Hypertension Kidney Injury
Background: IgA nephropathy (IgAN), a major cause of primary glomerulonephritis, is closely associated with malignant hypertension (MHT). This study aimed to explore the clinicopathological characteristics and renal prognosis of patients with IgAN combined with malignant hypertension kidney injury (IgAN‐MHT) and investigate the associations of clinicopathological indicators with prognosis. Methods: In this single‐center retrospective cohort study, patients diagnosed with IgAN‐MHT through kidney biopsy between January 1, 2008, and June 30, 2023, in our hospital were enrolled. Cox regression models were used to assess the associations between clinical indicators and renal prognosis in IgAN‐MHT patients. Results: A total of 70 patients were included in the analysis of renal function improvement. During a median follow‐up time of 9.4 months, 26 patients (37.1%) achieved renal function improvement. Patients in the improved renal function group had higher hemoglobin levels ( p = 0.003), lower serum creatinine levels ( p = 0.006), a higher proportion of patients using sulodexide ( p = 0.018), and a lower proportion of glomerulosclerosis ( p < 0.001). Multivariable Cox regression analysis indicated that a higher proportion of glomerulosclerosis was independently associated with a lower likelihood of renal function improvement (HR = 0.97, 95% CI = 0.96–0.99, p = 0.003), while sulodexide administration was independently associated with a higher likelihood of improvement (HR = 2.75, 95% CI = 1.18–6.41, p = 0.019). Conclusion: This study revealed that in IgAN‐MHT patients, a higher proportion of glomerulosclerosis was independently associated with poorer renal outcomes, while the use of sulodexide showed a significant independent association with improved renal function.
- Open Access
- 2 September 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-12
Significant proteinuria as a predictor of renal prognosis in malignant hypertension patients with thrombotic microangiopathy: a prospective cohort study
Malignant hypertension (mHTN) is the most severe form of hypertension. Thrombotic microangiopathy (TMA) serves as both a complication of mHTN and a contributor to its progression by exacerbating renal damage. Proteinuria is a common manifestation of mHTN. However, the impact of proteinuria on renal prognosis in mHTN patients with TMA is unclear. This observational cohort study included 276 mHTN-associated TMA patients based on renal biopsy from 2008 to 2023. Demographic characteristics, laboratory results, and histopathological findings were recorded and compared between the mild (< 1 g / 24 h) and significant (≥ 1 g / 24 h) proteinuria groups. Propensity score matching (PSM) was used to adjust for baseline differences. Cox regression model was employed to evaluate risk factors associated with renal prognosis. Among the 276 patients included in the study, 185 (67.0%) had significant proteinuria, while 91 (33.0%) had mild proteinuria at baseline. After PSM, 83 pairs of patients with mHTN-associated TMA were matched. Patients with significant proteinuria exhibited lower serum albumin, and higher ratio of global sclerosis compared to patients with mild proteinuria. Moreover, mHTN-associated TMA with significant proteinuria was independently associated with receiving renal replacement therapy (RRT) (adjusted hazard ratio (aHR), 1.30; 95% confidence interval (CI), 1.16–1.46; P < 0.001) compared with mild proteinuria. This association remained significant after PSM (aHR, 1.29; 95% CI, 1.13–1.47; P < 0.001). Furthermore, mHTN-associated TMA patients with significant proteinuria had a lower incidence of renal function recovery with a reduction in creatinine levels than in patients with mild proteinuria in the absence of intensive blood pressure control. In mHTN-associated TMA patients, the presence of significant proteinuria serves as a strong predictor of poor renal outcome. Not applicable.
- 2 September 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-12
Open AccessSignificant proteinuria as a predictor of renal prognosis in malignant hypertension patients with thrombotic microangiopathy: a prospective cohort study
Malignant hypertension (mHTN) is the most severe form of hypertension. Thrombotic microangiopathy (TMA) serves as both a complication of mHTN and a contributor to its progression by exacerbating renal damage. Proteinuria is a common manifestation of mHTN. However, the impact of proteinuria on renal prognosis in mHTN patients with TMA is unclear. This observational cohort study included 276 mHTN-associated TMA patients based on renal biopsy from 2008 to 2023. Demographic characteristics, laboratory results, and histopathological findings were recorded and compared between the mild (< 1 g / 24 h) and significant (≥ 1 g / 24 h) proteinuria groups. Propensity score matching (PSM) was used to adjust for baseline differences. Cox regression model was employed to evaluate risk factors associated with renal prognosis. Among the 276 patients included in the study, 185 (67.0%) had significant proteinuria, while 91 (33.0%) had mild proteinuria at baseline. After PSM, 83 pairs of patients with mHTN-associated TMA were matched. Patients with significant proteinuria exhibited lower serum albumin, and higher ratio of global sclerosis compared to patients with mild proteinuria. Moreover, mHTN-associated TMA with significant proteinuria was independently associated with receiving renal replacement therapy (RRT) (adjusted hazard ratio (aHR), 1.30; 95% confidence interval (CI), 1.16–1.46; P < 0.001) compared with mild proteinuria. This association remained significant after PSM (aHR, 1.29; 95% CI, 1.13–1.47; P < 0.001). Furthermore, mHTN-associated TMA patients with significant proteinuria had a lower incidence of renal function recovery with a reduction in creatinine levels than in patients with mild proteinuria in the absence of intensive blood pressure control. In mHTN-associated TMA patients, the presence of significant proteinuria serves as a strong predictor of poor renal outcome. Not applicable.
- Open Access
Association of renal cortical thickness and renal function in patients with malignant hypertension with thrombotic microangiopathy: a biopsy-based cohort study from China
Background: Malignant hypertension (mHTN) is an acute form of hypertension with multiorgan damage, including renal impairment. Renal cortical thickness (RCT) by ultrasonography is associated with renal function in kidney disease. However, the relationship between RCT and renal dysfunction in mHTN is not yet fully understood. Design: A cohort study. Setting: This was a study conducted between January 2008 and June 2023 at the First Affiliated Hospital of Sun Yat-sen University. Participants: A total of 292 mHTN patients with thrombotic microangiopathy (TMA) who underwent renal biopsy were included in the study. Primary outcomes and measures: Patient characteristics for RCT were examined using linear regression. The association between RCT and an increase in estimated glomerular filtration rate (eGFR) of ≥15% was analysed by Cox regression. RCT was analysed in two groups classified by median RCT. Results: Overall, patients with larger RCT exhibited a lower global sclerosis ratio and a lower proportion of intravascular thrombosis. RCT was strongly positively correlated with mean kidney length (coefficient B 1.018; 95% CI 0.638 to 1.397; p p p =0.001) and tubular atrophy/interstitial fibrosis ratio (coefficient B −0.880; 95% CI −1.569 to −0.192; p =0.012). Moreover, larger RCTs had a better renal function improvement of ≥15% increase in eGFR in patients with mHTN with TMA (HR 1.745; 95% CI 1.012 to 3.009; p =0.045). Conclusions: Smaller RCTs were correlated with a decline in renal function and deterioration of renal pathology. Furthermore, larger RCTs showed a better renal function improvement of ≥15% increase in eGFR in mHTN patients with TMA. RCT may be a predictive factor for renal damage in mHTN.
Open AccessAssociation of renal cortical thickness and renal function in patients with malignant hypertension with thrombotic microangiopathy: a biopsy-based cohort study from China
Background: Malignant hypertension (mHTN) is an acute form of hypertension with multiorgan damage, including renal impairment. Renal cortical thickness (RCT) by ultrasonography is associated with renal function in kidney disease. However, the relationship between RCT and renal dysfunction in mHTN is not yet fully understood. Design: A cohort study. Setting: This was a study conducted between January 2008 and June 2023 at the First Affiliated Hospital of Sun Yat-sen University. Participants: A total of 292 mHTN patients with thrombotic microangiopathy (TMA) who underwent renal biopsy were included in the study. Primary outcomes and measures: Patient characteristics for RCT were examined using linear regression. The association between RCT and an increase in estimated glomerular filtration rate (eGFR) of ≥15% was analysed by Cox regression. RCT was analysed in two groups classified by median RCT. Results: Overall, patients with larger RCT exhibited a lower global sclerosis ratio and a lower proportion of intravascular thrombosis. RCT was strongly positively correlated with mean kidney length (coefficient B 1.018; 95% CI 0.638 to 1.397; p p p =0.001) and tubular atrophy/interstitial fibrosis ratio (coefficient B −0.880; 95% CI −1.569 to −0.192; p =0.012). Moreover, larger RCTs had a better renal function improvement of ≥15% increase in eGFR in patients with mHTN with TMA (HR 1.745; 95% CI 1.012 to 3.009; p =0.045). Conclusions: Smaller RCTs were correlated with a decline in renal function and deterioration of renal pathology. Furthermore, larger RCTs showed a better renal function improvement of ≥15% increase in eGFR in mHTN patients with TMA. RCT may be a predictive factor for renal damage in mHTN.